More competition in the GLP-1 drug class, including the introduction of oral formulations, is expected to impact price, she said
Cardiac comorbidities at baseline were highly prevalent: 98.6% and 98.5% of patients had hypertension, 55.2% and 55.1% of patients had coronary artery disease, and 33.9% and 34% of patients had congestive heart failure, within the GLP1-RA and DPP4i groups, respectively
Cost of Treatment: For GLP-1 users, total health care costs (TCC) were $12,695 before starting, then rose to $20,165 in year one and $18,507 in year two
Changes in terms of diversity and richness have been associated with conditions, such as obesity, T2D, Parkinsons disease, cardiovascular disease, and IBD